

Invited Speakers

Nosa Bazuaye

University of Benin
Stem cell Transplant Centre
Benin, NIGERIA

Françoise Bernaudin

Centre Hospitalier Intercommunal
Créteil, FRANCE

Javier Bolanos Meade

Baltimore, USA

Marina Cavazzana-Calvo

Département de Biothérapie
Institut IMAGINE
Paris, FRANCE

Kenneth Enwerem

Omega Cares Foundation
NIGERIA

Lawrence Faulkner

Cure2Children Foundation
ITALY

Tayfun Güngör

Kinderspital Zürich
SWITZERLAND

Rupert Handgretinger

Children's Hospital
University of Tübingen, GERMANY

Julie Makani

Muhimbili University of Health and
Allied Sciences (MUHAS)
Dar es Salaam, TANZANIA

Pietro Sodani

Tor Vergata University
Rome, ITALY

Hongeng Suradej

Department of Pediatrics
Ramathibodi Hospital
Mahidol University
Bangkok, THAILAND

Cornelio Uderzo

Cure2Children Foundation
ITALY

General Information

Scientific Leadership

Prof. Dr. Selim Corbacioglu
Professor of Pediatrics
KUNO Children's Hospital
University Hospital Regensburg

Congress Venue

Hotel Goldenes Kreuz „Kaisersaal“
Haidplatz 7, 93047 Regensburg, Germany

Congress Management

Congress Division UK3, Britta Haseneder
University Hospital Regensburg
93042 Regensburg, Germany
Phone: +49 941 944-4230
Fax: +49 941 944-4233
E-mail: kongresse@ukr.de

Registration

Online registration under:
www.congress-registration.ukr.de

Congress Fee

Both days	100 €
Conference Dinner	50 €

Registration conditions

After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time.



Supported by a grant
of the Helga and Erwin Hartl Stiftung



Foto: UKR, Fotolia
April 2015



University Hospital Regensburg

KUNO Children's Hospital

Department of Pediatric
Hematology, Oncology
and Stem Cell Transplantation



INVITATION

3rd International Meeting of
the Sickle Cell Disease Cure and
Prevention Consortium (SCDC)

June 25th and 26th, 2015
Universitätsklinikum Regensburg

2. Announcement



Dear friends and colleagues!

We are happy to invite you to the third "Meeting of the Sickle Cell Disease Cure and Prevention Consortium" in Regensburg on June 25 and 26, 2015.

Mostly due to the lack of a suitable donor sickle cell disease (SCD) remained a medical orphan for transplant physicians up to now. With the substantial advancements in innovative transplant techniques using alternative donors SCD is becoming a curable disease for everybody. Additionally as a monogenetic disease gene therapy for SCD is just around the corner.

The main focus of this meeting is to harmonize standards and criteria and establish a road map for a prospective evaluation of the available modalities of haploidentical SCT for SCD, learn from the standard of care and receive an up-to-date outlook on gene therapy. With that regard this meeting is geared towards the expert in the field of SCT for hemoglobinopathies. It shall also serve as a forum for discussion and networking with colleagues from countries with a high prevalence of SCD in order to improve our understanding.

We are looking forward to welcome you in Regensburg!

With best regards



Prof. Dr. Selim Corbacioglu
Professor of Pediatrics KUNO Children's Hospital
University Hospital Regensburg

Nosa Bazuaye

Report of Hematopoietic stem cell transplantation for sickle cell disease and challenges in a poor resource country Nigeria: Nigerian group for blood and marrow transplantation

Kenneth Enwerem

Setting up a bone marrow transplant centre in a low resource setting: prospects and challenges

Lawrence Faulkner

Setting up BMT units for hemoglobinopathies in emerging countries: Update of the Cure-2Children Foundation experience

Julie Makani

Treatment options for sickle cell disease: Experience and perspectives from a sickle cell center in Africa

Cornelio Uderzo

Preliminary experience in Tanzania of three Italian NGOs to develop strategies aimed at reducing the morbidity and mortality of sickle cell disease in the country

Hongeng Suradej

Haplo-SCT/Post-Cy with Pre-transplant Immunosuppression followed by RIC Conditioning in Severe Thalassemia

Sodani Pietro

Alternative Donor SCT for SCD with T-Depletion Part 1

Corbacioglu, Selim

Alternative Donor SCT for SCD with T-Depletion Part 2

Tayfun Güngör

Reduced intensity conditioning – how much myeloablation do we need for non-malignant diseases?

Marina Cavazzana-Calvo

Updated results on gene therapy for hemoglobinopathies

Rupert Handgretinger

Ex vivo T-cell depletion in allogeneic transplantation for hemoglobinopathies

Françoise Bernaudin

MSD/MUD SCT in Sickle Cell Disease, State of the Art

Volker Witt

OPTIMATCH and the Prevention of Alloimmunization in Patienten with SCD

To be confirmed

Javier Bolanos Meade

Haplo-SCT/Post-Cy in SCD